| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
EVERY BREAKTHROUGH BEGINS WITH BELIEF November 2026 Corporate Presentation |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
EVERY BREAKTHROUGH BEGINS WITH BELIEF August 2026 Corporate Presentation |
| 02 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Pre-Funded Warrants to purchase up to 666,666 shares of Common Stock |
| 29 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Restarting Development in Rett Syndrome NGN-401 for Rett Syndrome Phase 1/2 Update June 29, 2026 |
| 08 Jun 2026 |
8-K: Regulation FD Disclosure
EVERY BREAKTHROUGH BEGINS WITH BELIEF June 2026 Corporate Presentation |
| 04 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 3, 2026, Neurogene Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The matters listed below were presented at the Annual Meeting. There were 11,387,407 shares of common stock present at t... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
EVERY BREAKTHROUGH BEGINS WITH BELIEF May 2026 Corporate Presentation |
| 20 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Ms. Shafer, a proven commercial leader in rare neurological diseases, will lead Neurogene’s commercial strategy and launch readiness for NGN-401 gene therapy for Rett syndrome |
| 24 Mar 2026 |
8-K: Results of Operations and Financial Condition
EVERY BREAKTHROUGH BEGINS WITH BELIEF March 2026 Corporate Presentation |
| 26 Feb 2026 |
8-K: Regulation FD Disclosure
Breakthrough Therapy designation granted based on interim NGN-401 Phase 1/2 data demonstrating clinically meaningful, durable and multidomain functional improvements |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
EVERY BREAKTHROUGH BEGINS WITH BELIEF January 2026 Corporate Presentation |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
Every Breakthrough BEGINS WITH BELIEF r r t r BE I S IT BELIEF Corporate Presentation November 2025 |
| 12 Nov 2025 |
8-K: Regulation FD Disclosure
Every Breakthrough BEGINS WITH BELIEF r r t r BE I S IT BELIEF NGN-401 Phase 1/2 Interim Data Update November 2025 |
| 06 Nov 2025 |
8-K: Regulation FD Disclosure
2 Disclaimer Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as... |
| 09 Oct 2025 |
8-K: Regulation FD Disclosure
2 Disclaimer Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as... |
| 11 Aug 2025 |
8-K: Results of Operations and Financial Condition
2 Disclaimer Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as... |
| 30 Jun 2025 |
8-K: Regulation FD Disclosure
2 Disclaimer Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as... |
| 12 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The purpose of this Neurogene Inc. 2023 Equity Incentive Plan (the “Plan”) is to promote and closely align the interests of employees, officers, non-employee directors and other individual service providers of Neurogene Inc. and its stoc... |
| 09 Jun 2025 |
8-K: Other Events
2 Disclaimer Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as... |
| 09 May 2025 |
8-K: Results of Operations and Financial Condition
On track to provide registrational trial plan update for NGN-401 gene therapy for Rett syndrome in the first half of 2025 |
Loading...